Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update

Steven M. Grunberg, David Osoba, Paul J. Hesketh, Richard J. Gralla, Sussanne Borjeson, Bernardo L. Rapoport, Andreas Du Bois, Maurizio Tonato

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Development of effective antiemetic therapy depends upon an understanding of both the antiemetic agents and the emetogenic challenges these agents are designed to address. New potential antiemetic agents should be studied in an orderly manner, proceeding from phase I to phase II open-label trials and then to randomized double-blind phase III trials comparing new agents and regimens to best standard therapy. Use of placebos in place of antiemetic therapy against highly or moderately emetogenic chemotherapy is unacceptable. Nausea and vomiting should be evaluated separately and for both the acute and delayed periods. Defining the emetogenicity of new antineoplastic agents is a challenge, since such data are often not reliably recorded during early drug development. A four-level classification system is proposed for emetogenicity of intravenous antineoplastic agents. A separate four-level classification system for emetogenicity of oral antineoplastic agents, which are often given over an extended period of time, is also proposed.

Original languageEnglish (US)
Pages (from-to)80-84
Number of pages5
JournalSupportive Care in Cancer
Volume13
Issue number2
DOIs
StatePublished - Feb 2005
Externally publishedYes

Fingerprint

Antiemetics
Antineoplastic Agents
Nausea
Vomiting
Therapeutics
Placebos
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Antiemetic
  • Classification
  • Emesis
  • Emetogenicity
  • Nausea

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. / Grunberg, Steven M.; Osoba, David; Hesketh, Paul J.; Gralla, Richard J.; Borjeson, Sussanne; Rapoport, Bernardo L.; Du Bois, Andreas; Tonato, Maurizio.

In: Supportive Care in Cancer, Vol. 13, No. 2, 02.2005, p. 80-84.

Research output: Contribution to journalArticle

Grunberg, SM, Osoba, D, Hesketh, PJ, Gralla, RJ, Borjeson, S, Rapoport, BL, Du Bois, A & Tonato, M 2005, 'Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update', Supportive Care in Cancer, vol. 13, no. 2, pp. 80-84. https://doi.org/10.1007/s00520-004-0718-y
Grunberg, Steven M. ; Osoba, David ; Hesketh, Paul J. ; Gralla, Richard J. ; Borjeson, Sussanne ; Rapoport, Bernardo L. ; Du Bois, Andreas ; Tonato, Maurizio. / Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. In: Supportive Care in Cancer. 2005 ; Vol. 13, No. 2. pp. 80-84.
@article{8db3c1b91fc14d2d8a52a2de1d77af2a,
title = "Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update",
abstract = "Development of effective antiemetic therapy depends upon an understanding of both the antiemetic agents and the emetogenic challenges these agents are designed to address. New potential antiemetic agents should be studied in an orderly manner, proceeding from phase I to phase II open-label trials and then to randomized double-blind phase III trials comparing new agents and regimens to best standard therapy. Use of placebos in place of antiemetic therapy against highly or moderately emetogenic chemotherapy is unacceptable. Nausea and vomiting should be evaluated separately and for both the acute and delayed periods. Defining the emetogenicity of new antineoplastic agents is a challenge, since such data are often not reliably recorded during early drug development. A four-level classification system is proposed for emetogenicity of intravenous antineoplastic agents. A separate four-level classification system for emetogenicity of oral antineoplastic agents, which are often given over an extended period of time, is also proposed.",
keywords = "Antiemetic, Classification, Emesis, Emetogenicity, Nausea",
author = "Grunberg, {Steven M.} and David Osoba and Hesketh, {Paul J.} and Gralla, {Richard J.} and Sussanne Borjeson and Rapoport, {Bernardo L.} and {Du Bois}, Andreas and Maurizio Tonato",
year = "2005",
month = "2",
doi = "10.1007/s00520-004-0718-y",
language = "English (US)",
volume = "13",
pages = "80--84",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update

AU - Grunberg, Steven M.

AU - Osoba, David

AU - Hesketh, Paul J.

AU - Gralla, Richard J.

AU - Borjeson, Sussanne

AU - Rapoport, Bernardo L.

AU - Du Bois, Andreas

AU - Tonato, Maurizio

PY - 2005/2

Y1 - 2005/2

N2 - Development of effective antiemetic therapy depends upon an understanding of both the antiemetic agents and the emetogenic challenges these agents are designed to address. New potential antiemetic agents should be studied in an orderly manner, proceeding from phase I to phase II open-label trials and then to randomized double-blind phase III trials comparing new agents and regimens to best standard therapy. Use of placebos in place of antiemetic therapy against highly or moderately emetogenic chemotherapy is unacceptable. Nausea and vomiting should be evaluated separately and for both the acute and delayed periods. Defining the emetogenicity of new antineoplastic agents is a challenge, since such data are often not reliably recorded during early drug development. A four-level classification system is proposed for emetogenicity of intravenous antineoplastic agents. A separate four-level classification system for emetogenicity of oral antineoplastic agents, which are often given over an extended period of time, is also proposed.

AB - Development of effective antiemetic therapy depends upon an understanding of both the antiemetic agents and the emetogenic challenges these agents are designed to address. New potential antiemetic agents should be studied in an orderly manner, proceeding from phase I to phase II open-label trials and then to randomized double-blind phase III trials comparing new agents and regimens to best standard therapy. Use of placebos in place of antiemetic therapy against highly or moderately emetogenic chemotherapy is unacceptable. Nausea and vomiting should be evaluated separately and for both the acute and delayed periods. Defining the emetogenicity of new antineoplastic agents is a challenge, since such data are often not reliably recorded during early drug development. A four-level classification system is proposed for emetogenicity of intravenous antineoplastic agents. A separate four-level classification system for emetogenicity of oral antineoplastic agents, which are often given over an extended period of time, is also proposed.

KW - Antiemetic

KW - Classification

KW - Emesis

KW - Emetogenicity

KW - Nausea

UR - http://www.scopus.com/inward/record.url?scp=17644419329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644419329&partnerID=8YFLogxK

U2 - 10.1007/s00520-004-0718-y

DO - 10.1007/s00520-004-0718-y

M3 - Article

VL - 13

SP - 80

EP - 84

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -